[{"id":"72596fa1-a0d4-4a25-9d18-6edd6d556738","acronym":"","url":"https://clinicaltrials.gov/study/NCT05505825","created_at":"2024-03-25T18:36:13.170Z","updated_at":"2024-07-02T16:35:01.060Z","phase":"Phase 1/2","brief_title":"A Study of AK104 in Combination With Chiauranib in Patients With Extensive Stage Small Cell Lung Cancer","source_id_and_acronym":"NCT05505825","lead_sponsor":"Akeso","biomarkers":" ATRX","pipe":" | ","alterations":" ATRX mutation","tags":["ATRX"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ATRX mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Kaitanni (cadonilimab) • Auraza (chiauranib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 08/26/2022","start_date":" 08/26/2022","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 01/01/2025","study_completion_date":" 01/01/2025","last_update_posted":"2024-05-24"},{"id":"8163efc5-651e-4b22-8baf-20113d9df6f9","acronym":"","url":"https://clinicaltrials.gov/study/NCT05336721","created_at":"2022-04-20T16:53:48.712Z","updated_at":"2024-07-02T16:36:11.782Z","phase":"Phase 2","brief_title":"A Phase II Study of Chiauranib in Combine With Capecitabine in TNBC","source_id_and_acronym":"NCT05336721","lead_sponsor":"Chipscreen Biosciences, Ltd.","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" ER negative • PGR negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER negative • PGR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e capecitabine • Auraza (chiauranib)"],"overall_status":"Recruiting","enrollment":" Enrollment 38","initiation":"Initiation: 11/05/2021","start_date":" 11/05/2021","primary_txt":" Primary completion: 03/15/2024","primary_completion_date":" 03/15/2024","study_txt":" Completion: 08/09/2024","study_completion_date":" 08/09/2024","last_update_posted":"2022-04-20"}]